Perceive Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.perceivebio.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Perceive Biotherapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06087458
- Locations
- 🇦🇺
Cerulea Clinical Trials, East Melbourne, Victoria, Australia
🇮🇱Rambam Medical Center, Haifa, Israel
🇦🇺Sydney Retina Clinic and Day Surgery, Sydney, New South Wales, Australia
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Phase 1
Active, not recruiting
- Conditions
- Age-related Macular DegenerationGeographic Atrophy
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Perceive Biotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05380492
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Retina Consultants of Texas, Bellaire, Texas, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
News
No news found